0001062993-16-007607.txt : 20160210 0001062993-16-007607.hdr.sgml : 20160210 20160210122444 ACCESSION NUMBER: 0001062993-16-007607 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160210 DATE AS OF CHANGE: 20160210 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87373 FILM NUMBER: 161404106 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Apex Capital Management CENTRAL INDEX KEY: 0001293585 IRS NUMBER: 311198068 STATE OF INCORPORATION: OH FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 8163 OLD YANKEE ROAD, SUITE E CITY: DAYTON STATE: OH ZIP: 45458 BUSINESS PHONE: 937-428-9222 MAIL ADDRESS: STREET 1: 8163 OLD YANKEE ROAD, SUITE E CITY: DAYTON STATE: OH ZIP: 45458 SC 13G 1 sch13g.htm SC 13G Apex Capital Management- Form SC 13G - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Enanta Pharmaceuticals
(Name of Issuer)

Common Stock, no par value
(Title of Class of Securities)

29251M106
(CUSIP Number)

December 31, 2015
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)

[_] Rule 13d-1(c)

[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


SCHEDULE 13G

CUSIP No. 29251M106

1

Names of Reporting Persons

Apex Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)      [ ]
(b)      [ ]

3

Sec Use Only

 

4

Citizenship or Place of Organization

United States



Number of
Shares
Beneficially
Owned by Each
Reporting Person With:

5

Sole Voting Power

1,234,383

6

Shared Voting Power

7

Sole Dispositive Power

1,234,383

8

Shared Dispositive Power

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,234,383

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

[ ]

11

Percent of class represented by amount in row (9)

5.0

12

Type of Reporting Person (See Instructions)

IA

Page 2 of 5



Item 1.

(a)

Name of Issuer: Enanta Pharmaceuticals

   
(b)

Address of Issuer’s Principal Executive Offices: 500 Arsenal St., Watertown, MA 02472


Item 2.

(a)

Name of Person Filing: Apex Capital Management

   
(b)

Address of Principal Business Office or, if None, Residence: 8163 Old Yankee St. Ste. E, Dayton OH 45458

   
(c)

Citizenship: United States

   
(d)

Title and Class of Securities: Common Shares, no par value

   
(e)

CUSIP No.: 29251M106


Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) [_] Broker or dealer registered under Section 15 of the Act;
       
  (b) [_] Bank as defined in Section 3(a)(6) of the Act;
       
  (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;
       
  (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;
       
  (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
       
  (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       
  (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       
(h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
(i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       
  (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
       
(k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
      ___________ 

Item 4. Ownership  

(a)

Amount Beneficially Owned: 1,234,383

Page 3 of 5



(b)

Percent of Class: 5%

   
(c)

Number of shares as to which such person has:


  (i)

Sole power to vote or to direct the vote: 1,234,383

     
  (ii)

Shared power to vote or to direct the vote:

     
  (iii)

Sole power to dispose or to direct the disposition of: 1,234,383

     
  (iv)

Shared power to dispose or to direct the disposition of:


Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of more than Five Percent on Behalf of Another Person.

Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Item 8. Identification and classification of members of the group.

Item 9. Notice of Dissolution of Group.

Item 10. Certifications.

Page 4 of 5


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: 02/10/2016

Michael Kalbfleisch

Michael Kalbfleisch, Vice President-Principal

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention:      Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Page 5 of 5